{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:02:31Z","timestamp":1776387751755,"version":"3.51.2"},"reference-count":250,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,14]]},"DOI":"10.1093\/eurheartj\/ehx419","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T13:48:57Z","timestamp":1504878537000},"page":"213-260","source":"Crossref","is-referenced-by-count":2342,"title":["2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS"],"prefix":"10.1093","volume":"39","author":[{"given":"Marco","family":"Valgimigli","sequence":"first","affiliation":[]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[]},{"given":"Robert A","family":"Byrne","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Anders","family":"Jeppsson","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"Kolh","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[]},{"given":"Mate","family":"Petricevic","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"given":"Glenn N","family":"Levine","sequence":"additional","affiliation":[]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[]},{"given":"Elliott","family":"Antman","sequence":"additional","affiliation":[]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[]},{"given":"Jean-Pierre","family":"Bassand","sequence":"additional","affiliation":[]},{"given":"Raffaele","family":"Bugiardini","sequence":"additional","affiliation":[]},{"given":"Mustafa","family":"Cikirikcioglu","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[]},{"given":"Michele","family":"De Bonis","sequence":"additional","affiliation":[]},{"given":"Victora","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gaemperli","sequence":"additional","affiliation":[]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[]},{"given":"Christian W","family":"Hamm","sequence":"additional","affiliation":[]},{"given":"Borja","family":"Ibanez","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[]},{"given":"Gregory","family":"Lip","sequence":"additional","affiliation":[]},{"given":"Massimo Francesco","family":"Piepoli","sequence":"additional","affiliation":[]},{"given":"Luc","family":"Pierard","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Schwerzmann","sequence":"additional","affiliation":[]},{"given":"Udo","family":"Sechtem","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Miguel Sousa","family":"Uva","sequence":"additional","affiliation":[]},{"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[]},{"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[]},{"given":"Frans","family":"Van de Werf","sequence":"additional","affiliation":[]},{"given":"Freek","family":"Verheugt","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Coca","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Ioan Mircea","family":"Coman","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gaemperli","sequence":"additional","affiliation":[]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Hugo A","family":"Katus","sequence":"additional","affiliation":[]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[]},{"given":"Massimo Francesco","family":"Piepoli","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"name":"ESC Committee for Practice Guidelines (CPG)","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Coca","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Ioan Mircea","family":"Coman","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gaemperli","sequence":"additional","affiliation":[]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Hugo A","family":"Katus","sequence":"additional","affiliation":[]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[]},{"given":"Massimo Francesco","family":"Piepoli","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"name":"ESC National Cardiac Societies","sequence":"additional","affiliation":[]},{"given":"Franz Xaver","family":"Roithinger","sequence":"additional","affiliation":[]},{"given":"Farid","family":"Aliyev","sequence":"additional","affiliation":[]},{"given":"Valeriy","family":"Stelmashok","sequence":"additional","affiliation":[]},{"given":"Walter","family":"Desmet","sequence":"additional","affiliation":[]},{"given":"Arman","family":"Postadzhiyan","sequence":"additional","affiliation":[]},{"given":"Georgios P","family":"Georghiou","sequence":"additional","affiliation":[]},{"given":"Zuzana","family":"Motovska","sequence":"additional","affiliation":[]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[]},{"given":"Toomas","family":"Marandi","sequence":"additional","affiliation":[]},{"given":"Tuomas","family":"Kiviniemi","sequence":"additional","affiliation":[]},{"given":"Sasko","family":"Kedev","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[]},{"given":"Robert Gabor","family":"Kiss","sequence":"additional","affiliation":[]},{"given":"Ingibjorg Jona","family":"Gudmundsdottir","sequence":"additional","affiliation":[]},{"given":"Eug\u00e8ne P","family":"McFadden","sequence":"additional","affiliation":[]},{"given":"Eli","family":"Lev","sequence":"additional","affiliation":[]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[]},{"given":"Akhmetzhan","family":"Sugraliyev","sequence":"additional","affiliation":[]},{"given":"Edmond","family":"Haliti","sequence":"additional","affiliation":[]},{"given":"Erkin","family":"Mirrakhimov","sequence":"additional","affiliation":[]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[]},{"given":"Birute","family":"Petrauskiene","sequence":"additional","affiliation":[]},{"given":"Steve","family":"Huijnen","sequence":"additional","affiliation":[]},{"given":"Caroline Jane","family":"Magri","sequence":"additional","affiliation":[]},{"given":"Rhizlan","family":"Cherradi","sequence":"additional","affiliation":[]},{"given":"Jurrien M","family":"Ten Berg","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Eritsland","sequence":"additional","affiliation":[]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[]},{"given":"Carlos Tavares","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Dmitry","family":"Duplyakov","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Zavatta","sequence":"additional","affiliation":[]},{"given":"Nebojsa M","family":"Antonijevic","sequence":"additional","affiliation":[]},{"given":"Zuzana","family":"Motovska","sequence":"additional","affiliation":[]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[]},{"given":"Antonio Tello","family":"Montoliu","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Varenhorst","sequence":"additional","affiliation":[]},{"given":"Dimitri","family":"Tsakiris","sequence":"additional","affiliation":[]},{"given":"Faouzi","family":"Addad","sequence":"additional","affiliation":[]},{"given":"Sinan","family":"Aydogdu","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"Parkhomenko","sequence":"additional","affiliation":[]},{"given":"Tim","family":"Kinnaird","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2017,8,26]]},"reference":[{"key":"key\n\t\t\t\t20180328133729_ehx419-B1","author":"Population Division"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4244\/EIJV11I1A11","article-title":"Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey","volume":"11","author":"Valgimigli","year":"2015","journal-title":"EuroIntervention"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B5","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/heartjnl-2011-300129","article-title":"Use of risk scores in acute coronary syndromes","volume":"98","author":"Bueno","year":"2012","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B8","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.CIR.101.22.2557","article-title":"Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients","volume":"101","author":"Boersma","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B10","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B11","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjcard.2010.12.009","article-title":"In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry(R)-GWTG","volume":"107","author":"Mathews","year":"2011","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B13","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy","volume":"4","author":"Costa","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11606-007-0498-4","article-title":"Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial","volume":"23","author":"Mahaffey","year":"2008","journal-title":"J Gen Intern Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1\u2009year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B16","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2\u2009year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"key\n\t\t\t\t20180328133729_ehx419-B19","doi-asserted-by":"crossref","first-page":"e002053","DOI":"10.1161\/CIRCINTERVENTIONS.114.002053","article-title":"Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions","volume":"8","author":"Koskinas","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jacc.2007.04.092","article-title":"Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study","volume":"50","author":"Campo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B23","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u2009months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.114.013570","article-title":"Prasugrel plus aspirin beyond 12\u2009months is associated with improved outcomes after TAXUS Libert\u00e9 paclitaxel-eluting coronary stent placement","volume":"131","author":"Garratt","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B29","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B32","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.114.011319","article-title":"Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified","volume":"130","author":"Valgimigli","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B36","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.114.011320","article-title":"Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy","volume":"130","author":"Collet","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B38","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B39","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B41","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B42","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B43","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B44","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcin.2016.04.014","article-title":"Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials","volume":"9","author":"Ferrante","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(84)92446-2","article-title":"Improved aortocoronary bypass patency by low-dose aspirin (100\u2009mg daily). Effects on platelet aggregation and thromboxane formation","volume":"1","author":"Lorenz","year":"1984","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B47","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B48","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/eurheartj\/ehn417","article-title":"Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study","volume":"30","author":"Jolly","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCULATIONAHA.114.014992","article-title":"Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study","volume":"132","author":"Xian","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B52","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B53","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.84.5.2054","article-title":"Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris","volume":"84","author":"Montalescot","year":"1991","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B56","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B57","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B58","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B59","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B60","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B61","first-page":"871","article-title":"Bedside monitoring of antiplatelet therapy for coronary stenting","volume":"368","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B62","first-page":"2","article-title":"Antiplatelet therapy. ARCTIC leaves platelet testing out in the cold","volume":"10","author":"Lim","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B63","doi-asserted-by":"crossref","first-page":"e570; author reply e571","DOI":"10.1161\/CIRCULATIONAHA.111.075002","article-title":"Letter by De Miguel Castro et al regarding article, \u201cPlatelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial\u201d","volume":"125","author":"De Miguel Castro","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B64","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B65","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1160\/th15-05-0394","article-title":"Point-of-care genetic profiling and\/or platelet function testing in acute coronary syndrome","volume":"115","author":"Collet","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B67","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450\u20092C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B69","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450\u20092C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B70","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B71","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(09)61246-0","article-title":"Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial","volume":"374","author":"Taha","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B73","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B74","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B75","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B76","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B77","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1345\/aph.1M051","article-title":"Drug-drug interaction between clopidogrel and the proton pump inhibitors","volume":"43","author":"Norgard","year":"2009","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B78","doi-asserted-by":"crossref","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B79","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2016.01.015","article-title":"Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial","volume":"174","author":"Gargiulo","year":"2016","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B81","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B82","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.17235\/reed.2016.4232\/2016","article-title":"Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva","volume":"108","author":"de la Coba Ortiz","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","author":"Kerneis","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B86","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCULATIONAHA.111.019745","article-title":"Antiplatelet therapy and proton pump inhibition: clinician update","volume":"125","author":"Moukarbel","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ehjcvp\/pvv036","article-title":"Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events","volume":"2","author":"Fortuna","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B88","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/2048872614564082","article-title":"In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study","volume":"4","author":"Bagai","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B90","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2048872614547449","article-title":"MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel\u2013the European MULTIPRAC Registry","volume":"4","author":"Clemmensen","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B91","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2013.10.010","article-title":"In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome","volume":"167","author":"Alexopoulos","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B92","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcin.2016.02.039","article-title":"Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study","volume":"9","author":"Franchi","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B93","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","article-title":"Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2)","volume":"63","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B94","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study","volume":"56","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B95","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B96","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B97","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B98","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B99","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial","volume":"36","author":"Costa","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B101","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B102","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B103","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B104","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12\u2009months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B105","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B106","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B107","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B108","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B109","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B110","first-page":"1373","article-title":"Duration of dual antiplatelet therapy after drug-eluting stents","volume":"372","author":"Mauri","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B111","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B112","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1\u2009year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B113","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","article-title":"Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B114","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcin.2015.10.001","article-title":"Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents","volume":"9","author":"Hermiller","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B116","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2016.04.118","article-title":"Duration of dual antiplatelet therapy after various drug-eluting stent implantation","volume":"215","author":"Sharma","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B117","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/ehv712","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence","volume":"37","author":"Palmerini","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B118","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B119","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","article-title":"Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials","volume":"387","author":"Cassese","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B120","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3\u2009year, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B121","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","article-title":"Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings","volume":"66","author":"R\u00e4ber","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2015.04.063","article-title":"A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial","volume":"66","author":"Alfonso","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B123","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcin.2013.08.011","article-title":"A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial","volume":"7","author":"Xu","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B124","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(12)61964-3","article-title":"Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial","volume":"381","author":"Byrne","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B125","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2012.07.040","article-title":"SeQuent Please World Wide Registry: clinical results of SeQuent Please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study","volume":"18","author":"W\u00f6hrle","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B126","doi-asserted-by":"crossref","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12\u2009months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B127","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B128","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jama.2015.1671","article-title":"Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial","volume":"313","author":"Kereiakes","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B129","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B131","doi-asserted-by":"crossref","first-page":"g6427","DOI":"10.1136\/bmj.g6427","article-title":"Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis","volume":"349","author":"Valgimigli","year":"2014","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B132","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"Bonaa","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B133","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2013.12.006","article-title":"A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent)","volume":"63","author":"Alfonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B134","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","article-title":"Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B135","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B136","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B137","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B138","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B139","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B140","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B141","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B142","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2015.08.058","article-title":"Impact of greater than 12-month dual antiplatelet therapy duration on mortality: drug-specific or a class-effect? A meta-analysis","volume":"201","author":"Costa","year":"2015","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B143","first-page":"1034","article-title":"Three, six or twelve months of dual antiplatelet therapy after drug-eluting stent implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11\u2009473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B144","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B145","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B146","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2015","journal-title":"EuroIntervention"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B147","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B148","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12893-015-0096-z","article-title":"Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials","volume":"15","author":"Verma","year":"2015","journal-title":"BMC Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B149","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jocs.12074","article-title":"Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis","volume":"28","author":"Deo","year":"2013","journal-title":"J Card Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B150","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B151","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B152","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","article-title":"Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study","volume":"37","author":"Hansson","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B153","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ejcts\/ezw149","article-title":"Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment","volume":"50","author":"Tomsic","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B154","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1592\/phco.28.3.376","article-title":"Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting","volume":"28","author":"Pickard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/hrt.2004.058396","article-title":"Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis","volume":"92","author":"Purkayastha","year":"2006","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B156","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B157","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.athoracsur.2012.07.086","article-title":"2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations","volume":"94","author":"Ferraris","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B158","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B159","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamacardio.2016.3028","article-title":"Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting","volume":"1","author":"Gherli","year":"2016","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B161","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B162","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO)","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B163","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/bja\/aev164","article-title":"Aspirin and coronary artery surgery: a systematic review and meta-analysis","volume":"115","author":"Hastings","year":"2015","journal-title":"Br J Anaesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B164","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJMoa1507688","article-title":"Stopping vs. continuing aspirin before coronary artery surgery","volume":"374","author":"Myles","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B165","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0003-4975(00)02133-0","article-title":"Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients","volume":"70","author":"Dacey","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B166","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/bja\/aet339","article-title":"Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor","volume":"112","author":"Hansson","year":"2014","journal-title":"Br J Anaesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B167","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/EJA.0000000000000348","article-title":"The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study","volume":"33","author":"Martin","year":"2016","journal-title":"Eur J Anaesthesiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B168","doi-asserted-by":"crossref","first-page":"e002786","DOI":"10.1161\/CIRCINTERVENTIONS.115.002786","article-title":"Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study","volume":"8","author":"O'Connor","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B169","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/bja\/aew189","article-title":"Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study","volume":"117","author":"Malm","year":"2016","journal-title":"Br J Anaesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B170","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","article-title":"Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses","volume":"9","author":"Storey","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B171","first-page":"633","article-title":"Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery","volume":"51","author":"Hansson","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B172","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2010.03.108","article-title":"Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery","volume":"56","author":"Kwak","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B173","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.athoracsur.2010.09.022","article-title":"Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines","volume":"91","author":"Ranucci","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B174","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/bja\/aeu315","article-title":"Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery","volume":"113","author":"Ranucci","year":"2014","journal-title":"Br J Anaesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","article-title":"Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B176","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","article-title":"Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients","volume":"3","author":"Vries","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B177","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2013.07.017","article-title":"Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting","volume":"112","author":"Nocerino","year":"2013","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B178","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/heartjnl-2012-302449","article-title":"Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study","volume":"98","author":"Mannacio","year":"2012","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B179","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B180","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B181","doi-asserted-by":"crossref","first-page":"e012604","DOI":"10.1136\/bmjopen-2016-012604","article-title":"Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland","volume":"6","author":"Prami","year":"2016","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B182","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/ehjci\/jev283","article-title":"Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis","volume":"17","author":"Iannaccone","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B183","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B184","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B185","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B186","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B187","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B188","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.thromres.2014.05.034","article-title":"The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience","volume":"134","author":"Barnes","year":"2014","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B189","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Roldan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B190","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B191","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B192","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B193","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B194","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B195","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B196","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B197","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B198","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B199","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B200","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B201","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B202","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B203","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/jama.2013.278787","article-title":"Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents","volume":"310","author":"Hawn","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B204","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B205","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","article-title":"2014 ESC\/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B206","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.2007.06968.x","article-title":"Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology","volume":"140","author":"Chee","year":"2008","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B207","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacc.2014.07.944","article-title":"2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"64","author":"Fleisher","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B208","article-title":"Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis","author":"Siller-Matula","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B209","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/SLA.0b013e31824b45af","article-title":"The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery","volume":"255","author":"Glance","year":"2012","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4244\/EIJV10I1A8","article-title":"Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies","volume":"10","author":"Rossini","year":"2014","journal-title":"EuroIntervention"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B211","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/ejvs.2001.1506","article-title":"Haemorrhage associated with combined clopidogrel and aspirin therapy","volume":"22","author":"Chapman","year":"2001","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B212","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1378\/chest.129.3.734","article-title":"Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans","volume":"129","author":"Ernst","year":"2006","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B213","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00000542-200409000-00030","article-title":"Perioperative hemorrhage and combined clopidogrel and aspirin therapy","volume":"101","author":"Moore","year":"2004","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B214","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","article-title":"Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis","volume":"257","author":"Burger","year":"2005","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:THRO.0000036025.07348.f1","article-title":"The efficacy and safety of perioperative antiplatelet therapy","volume":"17","author":"Merritt","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B216","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jcin.2010.03.021","article-title":"Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry","volume":"3","author":"Berger","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B217","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.amjcard.2009.06.038","article-title":"Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents","volume":"104","author":"van Kuijk","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B218","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/10245330701554623","article-title":"Alterations of hemostasis after laparoscopic and open surgery","volume":"12","author":"Diamantis","year":"2007","journal-title":"Hematology"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B219","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1111\/j.1538-7836.2007.02694.x","article-title":"Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery","volume":"5","author":"Rajagopalan","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B220","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","article-title":"Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians","volume":"115","author":"Grines","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B221","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B222","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2007.09.003","article-title":"ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery","volume":"50","author":"Fleisher","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B223","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.jacc.2008.01.063","article-title":"Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions","volume":"51","author":"Brar","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B224","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B225","doi-asserted-by":"crossref","first-page":"f6530","DOI":"10.1136\/bmj.f6530","article-title":"Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis","volume":"347","author":"Navarese","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B226","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.jacc.2016.09.967","article-title":"Risk associated with surgery within 12\u2009months after coronary drug-eluting stent implantation","volume":"68","author":"Egholm","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B227","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/SLA.0000000000001246","article-title":"The incremental risk of coronary stents on postoperative adverse events: a matched cohort study","volume":"263","author":"Holcomb","year":"2016","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B228","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ejcts\/ezu366","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"46","author":"Kolh","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B229","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/bja\/aep373","article-title":"Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of \u2018bridging\u2019 antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel","volume":"104","author":"Savonitto","year":"2010","journal-title":"Br J Anaesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pharmthera.2016.01.004","article-title":"Current status of data on cangrelor","volume":"159","author":"Qamar","year":"2016","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B231","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B232","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcin.2009.11.017","article-title":"Perioperative management of patients with drug-eluting stents","volume":"3","author":"Abualsaud","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B233","first-page":"153","article-title":"Perioperative management of antiplatelet therapy in patients with drug-eluting stents","volume":"4","author":"Dimitrova","year":"2012","journal-title":"HSR Proc Intensive Care Cardiovasc Anesth"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B234","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0735-1097(00)00521-0","article-title":"Catastrophic outcomes of noncardiac surgery soon after coronary stenting","volume":"35","author":"Kaluza","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B235","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B236","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B237","doi-asserted-by":"crossref","first-page":"A480","DOI":"10.1016\/j.jval.2014.08.1389","article-title":"Estimating The value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients","volume":"17","author":"Bay","year":"2014","journal-title":"Value Health"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B238","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.vph.2015.11.085","article-title":"Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: analysis of 314 patients","volume":"80","author":"De Servi","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B239","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1586\/14779072.2013.811972","article-title":"Cangrelor in patients undergoing cardiac surgery: the BRIDGE study","volume":"11","author":"Voeltz","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ccd.26653","article-title":"Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials","volume":"89","author":"Sawaya","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B241","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jcin.2016.05.046","article-title":"Impact of sex on 2-year clinical outcomes in patients treated with 6-month or 24-month dual-antiplatelet therapy duration: a pre-specified analysis from the PRODIGY trial","volume":"9","author":"Gargiulo","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B242","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the Randomized Dual Antiplatelet Therapy study","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B243","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B244","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B245","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","article-title":"Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 P-TIMI 50)","volume":"133","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B246","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B247","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B248","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jcin.2014.05.017","article-title":"Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry","volume":"7","author":"Armstrong","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B249","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328133729_ehx419-B250","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2013.02.044","article-title":"Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status","volume":"61","author":"Amin","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/3\/213\/23455993\/ehx419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T07:43:21Z","timestamp":1570088601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/3\/213\/4095043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,26]]},"references-count":250,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,8,26]]},"published-print":{"date-parts":[[2018,1,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,14]]},"published":{"date-parts":[[2017,8,26]]}}}